메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Medtronic executives to speak at upcoming investor conferences

GALWAY, Ireland, Aug. 29, 2025 -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference Thursday, September 4, 2025, at 8:00 a.m. EDT (7:00 a.m. CDT)Geoff Martha, Medtronic chairman and chief executive officer, and Thierry Piéton, Medtronic executive vice president and chief financial officer, will answer questions on the company. Morgan Stanley 23rd Annual Global Healthcare ConferenceMonday, September 8, 2025, at 4:50 p.m. EDT (3:50 p.m.
- 김갑성 기자
- 2025-08-29 23:51
Lifezoom Updates: Refining Efficient Light Therapy Products Based on Customer Insights

NEW YORK, Aug. 29, 2025 -- Since its launch, Lifezoom's light therapy devices have steadily become a promising contender in the industry. However, users' feedback revealed that the original single blue light mode is primarily suitable for short-term use, which highlights the limited benefits of blue light, with most customers calling for higher efficiency at specific wavelengths. As Lifezoom's CEO mentioned, "User feedback is our most important guide. In this instance, we acted quickly to enhance the red light wand, reflecting Lifezoom's core philosophy of putting user needs at th
- 김갑성 기자
- 2025-08-29 23:21
코벤트리, 라페터스의 영업비밀 주장 반박

[ 메디채널 황정호 기자 ] -- 기대수명 예측 정확성에 대한 투명성 촉구 -- 라페터스의 폐업이 임박함에 따라 영업비밀 보호 주장 근거 소멸 주장 탤러해시, 플로리다주, 2025년 8월 29일 -- 사망보험금 유동화(life settlement) 시장 선도기업 코벤트리 퍼스트 LLC(Coventry First LLC, 이하 '코벤트리')가 금주 법으로 규정된 기대수명 감사 보고서 공개를 막으려는 라페터스 솔루션스(Lapetus Solutions, 이하 '라페터스')의 시도에 반대하는 법적 답변서를 제출했다. 이번 대응 조치로 코벤트리는 사망보험금 유동화 시장의 건전성을 유지하기 위해서는 정확하고 투명한 기대수명 추정치가 반드시 필요하다는 기존 입장을 재확인했다. 이와 동시에 코벤트리는 라페터스가 2025년 8월 31일 폐업을 발표한 만큼 영업비밀 보호 주장은 더 이상 성립하지 않는다는 주장이 담긴 약식판결 신청서도 자체적으로 제출했다. 플로리다주 법에 따르면 기대수명 산정기관은 각 감사 이전 5개 연도에 대한 3년 주기 기대수명 감사 보고서를 플로리다 보험 규제국(Office of Insurance Regulat
- 황정호 기자
- 2025-08-29 22:04
Guo Guangchang: Fosun Strives to Break Through in Advantageous Sectors and Reach the Global Pinnacle

HONG KONG, Aug. 29, 2025 -- On the morning of 29 August, Guo Guangchang, Chairman of Fosun International, stated at the Company's 2025 interim results presentation that Fosun will continue to increase investment in biopharmaceuticals and focus on deepening and thoroughly developing its advantageous industries to secure a commanding global position. The interim results presentation was held in Shanghai this morning, with attendees including Chairman Guo Guangchang, Co-Chairman Wang Qunbin, Co-CEO Chen Qiyu, Co-CEO Xu Xiaoliang, CFO Gong Ping, along with numerous investors and analysts.&
- 황정호 기자
- 2025-08-29 20:13
United Imaging Healthcare Reports 2025H1 Financial Results: Achieves Record Revenue in Overseas market

SHANGHAI, Aug. 29, 2025 -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first half of 2025, maintaining steady growth. The company's revenue and net profit attributable to ordinary shareholders after deducting non-recurring profit or loss reached CNY 6.02 billion and 0.97 billion for 2025H1, representing a year-over-year increase of 12.79% and 21.01% respectively. The company's revenue growth was primarily fueled by continuous launch of innovative high-end products, now widely
- 김갑성 기자
- 2025-08-29 20:00
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

[ 메디채널 김갑성 기자 ] Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market Expansion Trading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the Nasdaq Global Market on August 29, 2025, under the ticker symbols "YDES" and "YDESW" NEW YORK, Aug. 29, 2025 -- YD Bio Limited ("YD Bio Ltd" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completio
- 김갑성 기자
- 2025-08-29 19:30
Taiwan's Smart Healthcare Pavilion Presents Precision Oncology and Telemedicine Applications at Taiwan Expo USA 2025

DALLAS, Aug. 29, 2025 -- At Taiwan Expo USA 2025 in Dallas, the Smart Healthcare Pavilion, organized by the International Trade Administration (TITA) and the Taiwan External Trade Development Council (TAITRA), highlighted Taiwan's accelerating role in global digital health innovation. The pavilion brought together leading organizations introducing new approaches across telemedicine, artificial intelligence (AI), precision medicine, and next-generation medical services, as reported by GeneOnline. One key highlight was CancerFree Biotech Ltd., which has advanced precision oncolog
- 김갑성 기자
- 2025-08-29 17:32
MGI Tech and JCBio Announce Collaboration on DCS Lab Project to Advance Multi-Omics Innovation in South Korea

CHANGCHUN, China, Aug. 29, 2025 -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and JCBio Co., Ltd. ("JCBio"), a leading South Korean biotechnology company, have signed a Memorandum of Understanding (MoU) to launch the DCS Lab Project, a landmark collaboration. The initiative aims to accelerate multi-omics research, novel sequencing applications, precision medicine, clinical translation, and AI-driven data insights in South Korea. By combining MGI's advanced omics technologies with
- 김갑성 기자
- 2025-08-29 17:29
Gateway to Growth: Innovation and Opportunity at the 8th CIIE

SHANGHAI, Aug. 29, 2025 -- Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a vital gateway for global enterprises. With preparations for the 8th CIIE well underway, the expo is set to once again showcase innovation, foster cooperation, and expand access to the Chinese dynamic market. Leveraging the vital platform for global enterprises to access the Chinese massive market, many exhibitors have grown from participants into investors, while numerous exhibits have been transformed into marketable goods. Novartis, for instance, debute
- 김갑성 기자
- 2025-08-29 16:44
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

[ 메디채널 김갑성 기자 ] 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in children and adults with Dravet syndrome or Lennox-Gastaut syndrome[2] Data provide insights on developmental and epileptic encephalopathies (DEEs), including a qualitative study addressing diagnostic challenges and benefits in adult care settings, and a caregiver survey exploring the dai
- 김갑성 기자
- 2025-08-29 14:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-09-04_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 04일 12시 20분